Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

Jeffrey L. Wolf; David Siegel; Hartmut Goldschmidt; Katharine Hazell; Priscille M. Bourquelot; Bourras R. Bengoudifa; Jeffrey Matous; Ravi Vij; Margarida De Magalhaes-Silverman; Rafat Abonour; Kenneth C. Anderson; Sagar Lonial

doi:10.3109/10428194.2012.661175

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

Jeffrey L. Wolf, David Siegel, Hartmut Goldschmidt, Katharine Hazell, Priscille M. Bourquelot, Bourras R. Bengoudifa, Jeffrey Matous, Ravi Vij, Margarida De Magalhaes-Silverman, Rafat Abonour, Kenneth C. Anderson, Sagar Lonial

Research output: Contribution to journal › Letter › peer-review

112 Scopus citations

Original language	English
Pages (from-to)	1820-1823
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	53
Issue number	9
DOIs	https://doi.org/10.3109/10428194.2012.661175
State	Published - Sep 2012

Access to Document

10.3109/10428194.2012.661175

Cite this

Wolf, J. L., Siegel, D., Goldschmidt, H., Hazell, K., Bourquelot, P. M., Bengoudifa, B. R., Matous, J., Vij, R., De Magalhaes-Silverman, M., Abonour, R., Anderson, K. C., & Lonial, S. (2012). Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 53(9), 1820-1823. https://doi.org/10.3109/10428194.2012.661175

@article{52b81a06b66b408b9cb5570ef59216fe,

title = "Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma",

author = "Wolf, {Jeffrey L.} and David Siegel and Hartmut Goldschmidt and Katharine Hazell and Bourquelot, {Priscille M.} and Bengoudifa, {Bourras R.} and Jeffrey Matous and Ravi Vij and {De Magalhaes-Silverman}, Margarida and Rafat Abonour and Anderson, {Kenneth C.} and Sagar Lonial",

note = "Funding Information: We thank the patients and the investigators, institutions, and their staff for their support. We thank James E. Bradner (Harvard Medical School and Dana-Farber Cancer Institute, USA) for expert discussion on HDAC and proteasome inhibition and enthusiastic support for this clinical study concept. The authors thank Dina Marenstein, PhD, of Chameleon Communications International and William Fazzone, PhD, of Articulate Science for editorial support funded by Novartis Pharmaceuticals.",

year = "2012",

month = sep,

doi = "10.3109/10428194.2012.661175",

language = "English",

volume = "53",

pages = "1820--1823",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

number = "9",

}

Wolf, JL, Siegel, D, Goldschmidt, H, Hazell, K, Bourquelot, PM, Bengoudifa, BR, Matous, J, Vij, R, De Magalhaes-Silverman, M, Abonour, R, Anderson, KC & Lonial, S 2012, 'Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma', Leukemia and Lymphoma, vol. 53, no. 9, pp. 1820-1823. https://doi.org/10.3109/10428194.2012.661175

TY - JOUR

T1 - Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

AU - Wolf, Jeffrey L.

AU - Siegel, David

AU - Goldschmidt, Hartmut

AU - Hazell, Katharine

AU - Bourquelot, Priscille M.

AU - Bengoudifa, Bourras R.

AU - Matous, Jeffrey

AU - Vij, Ravi

AU - De Magalhaes-Silverman, Margarida

AU - Abonour, Rafat

AU - Anderson, Kenneth C.

AU - Lonial, Sagar

N1 - Funding Information: We thank the patients and the investigators, institutions, and their staff for their support. We thank James E. Bradner (Harvard Medical School and Dana-Farber Cancer Institute, USA) for expert discussion on HDAC and proteasome inhibition and enthusiastic support for this clinical study concept. The authors thank Dina Marenstein, PhD, of Chameleon Communications International and William Fazzone, PhD, of Articulate Science for editorial support funded by Novartis Pharmaceuticals.

PY - 2012/9

Y1 - 2012/9

UR - http://www.scopus.com/inward/record.url?scp=84862878624&partnerID=8YFLogxK

U2 - 10.3109/10428194.2012.661175

DO - 10.3109/10428194.2012.661175

M3 - Letter

C2 - 22288662

AN - SCOPUS:84862878624

SN - 1042-8194

VL - 53

SP - 1820

EP - 1823

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 9

ER -

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

Access to Document

Other files and links

Cite this